Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Pharmaceutical Pricing: How Much for The Risk Of Non-Cure? (CROSBI ID 639963)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa

Mance, Davor ; Mance, Diana ; Vitezić, Dinko Pharmaceutical Pricing: How Much for The Risk Of Non-Cure? // Clinical therapeutics. 2016. str. 17-18 doi: 10.1016/j.clinthera.2016.07.128

Podaci o odgovornosti

Mance, Davor ; Mance, Diana ; Vitezić, Dinko

engleski

Pharmaceutical Pricing: How Much for The Risk Of Non-Cure?

Pharmacoeconomics is a blend of economic methodology with clinical pharmacology and outcomes research with an objective to provide for more efficient and cost-effective treatments. By doing this, pharmacoeconomics is constantly faced with ethical decision-making problems. The problem lies with the attempt of using epistemologically objective methods on an intrinsically ontologically subjective subject matter. In this work we discuss the possibility of an epistemologically objective methodology of integration of measures of risk of non-cure into pharmaceutical pricing schemes.

Pharmacoeconomics ; Pharmaceutical Pricing ; Risk Of Non-Cure ; Sustained Virological Response

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

17-18.

2016.

nije evidentirano

objavljeno

10.1016/j.clinthera.2016.07.128

Podaci o matičnoj publikaciji

Clinical therapeutics

Elsevier

0149-2918

Podaci o skupu

European Association for Clinical Pharmacology and Therapeutics (EACPT) Focus Meeting 2016: How to Assess Medicines from Research to Clinical Practice? Efficacy, Effectiveness, and Economic– 3E Assessment

predavanje

06.10.2016-09.10.2016

Opatija, Hrvatska

Povezanost rada

Matematika, Kliničke medicinske znanosti, Ekonomija

Poveznice